

INDEX

Note: Page numbers of article titles are in **boldface** type.

- N-Acetylcysteine, in mycobacterial specimen decontamination, 558-559
- Acid-fast bacteria, smears of, interpretation of, 554-557
- microscopic examination of, 553-554
- in developing countries, 705-707
- predictive value of, 556-557
- preparation of, 556, 681
- quality control of, 658-659
- safety with, 530
- test sensitivity of, 667-668
- Acquired immunodeficiency syndrome. See *Human immunodeficiency virus infection*.
- Aerosols, of mycobacteria, sources of, 529
- Agar disk diffusion method, in drug susceptibility testing, of atypical mycobacteria, 653
- Agar disk elution method, in drug susceptibility testing, of atypical mycobacteria, 653
- Agar 7H11 plates, in drug susceptibility testing, of mycobacteria, 644-645
- AIDS. See *Human immunodeficiency virus infection*.
- Air filters, for biological safety cabinets, in mycobacteriology, 530-535
- Aminosalicylic acid, pharmacokinetics of, 720-721
- Amplicor systems, for polymerase chain reaction, in mycobacteriology, 630-631, 683
- Amplification techniques, in mycobacteriology, 682-685. See also *Polymerase chain reaction*.
- Gen-Probe MTD system (transcription-mediated), 632-634, 682-683
- principles of, 617-619
- Antimycobacterial drugs, in mycobacterial infections, susceptibility testing of. See *Drug susceptibility testing, of mycobacteria*.
- therapeutic monitoring of, 717-729
- assay methods and technology for, 723-725
- mechanisms of action and, 719
- pharmacodynamic parameters of, 719
- pharmacokinetic parameters of, 718-721
- practical issues in, 722-723
- results interpretation in, 725-727
- Arylsulfatase, in mycobacterial identification, 572, 578, 581, 583, 587
- Association of State and Territorial Public Health Laboratory Directors, 731-743
- assessment activities of, 732-735
- conferences of, on mycobacteriology, 737-738
- fellowship program of, 740-741
- information transfer by, 740
- mission of, 731
- Pacific Islands laboratory case study of, 736-737
- policy development by, 735-738
- quality assurance activities of, 739-742
- self-assessment tools of, 741-742
- training programs of, 739-741
- Auramine rhodamine stain, for acid-fast bacteria, 554-555
- Automation, in mycobacteriology, culture equipment, 560, 562-563
- Azithromycin, in mycobacterial infections, 641
- BACTEC 12B system, in mycobacteriology, nucleic acid probes in, 608
- BACTEC NAP system, in mycobacteriology, quality control of, 661
- BACTEC systems, in mycobacteriology, in drug susceptibility testing, 645-646
- of *Mycobacterium avium* complex, 648-650

- BACTEC systems (*Continued*)
 p-nitro- α -acetyl-amino- β -hydroxypropionophenone in, 604-605
 procedure for, 560-564
 safety in, 530-531
- BACTEC TB system, cross-contamination in, prevention of, 666-667
- Benches, horizontal laminar flow, in mycobacteriology, 535-536
- Biocontainment, in mycobacteriology, primary, 531-538
 secondary, 538
- Biohazard bags, in mycobacteriology, 541
- Biological safety cabinets, in mycobacteriology, certification of, 536
 class I, 531-532
 class II, 532-535
 location of, 538
 operational suggestions for, 536-537
- Biosafety. *See Safety.*
- Blood culture, of mycobacteria, 561-562
- Bronchial alveolar lavage, in specimen collection, for mycobacteriology, 552
- Broth microdilution method, for drug susceptibility testing, of atypical mycobacteria, 652-653
- Capreomycin, pharmacokinetics of, 720-721
- Carbon usage test, in mycobacterial identification, 583, 587-588
- Catalase, in mycobacterial identification, 572, 578, 581, 583, 588-589
- Cell lysis, in polymerase chain reaction, 619
- Centrifugation, of mycobacterial samples, safety with, 529-530
- Cetyl pyridium chloride, in mycobacterial specimen decontamination, 558
- Chemiluminescence, for polymerase chain reaction, in mycobacteriology, 632-634
- Chromatography, in mycobacterial identification, gas-liquid, 605-606
 high-pressure liquid, 606-607
 liquid, quality control of, 661-662
- Clarithromycin, in mycobacterial infections, 641
- Clinical Laboratory Improvement Amendments, proficiency testing regulations of, 670-671
- Clofazimine, pharmacokinetics of, 720-721
- Clothing, protective, for mycobacteriology, 540-541
- College of American Pathologists, proficiency testing regulations of, 670-672
- Colonial morphology, in mycobacterial identification, 572, 578, 581, 583, 589-590
- Commercial systems, for polymerase chain reaction, in mycobacteriology, 630-631
- Cost-effectiveness, in mycobacteriology, in test utilization reduction, 754-755
 strategies for, 686-689
- Cultures, mycobacterial, blood, 561-562
 preparation of, 559-565, 681-682
 in developing countries, 706
 quality control of, 660-661
 safe handling of, 543-548
 slide, in drug susceptibility testing, 648
 specimen decontamination for, 558-559, 660
- Cycloserine, pharmacokinetics of, 720-721
- Decontamination, of specimens, for mycobacterial culture, 558-559
 quality control of, 660
- Developing countries, mycobacteriology in. *See Mycobacteriology, in developing countries.*
- Digoxigenin, in polymerase chain reaction detection step, 625-626
- Direct tests, of drug susceptibility, of mycobacteria, 643-645, 647-648
- Dithiothreitol, in mycobacterial specimen decontamination, 558
- DNA, amplification of, polymerase chain reaction in. *See Polymerase chain reaction.*
- DNA probes, in mycobacteriology, 573, 578, 581
 quality control of, 661
- Drug resistance, in tuberculosis, 515
 in developing countries, 699-701
 testing of. *See Drug susceptibility testing.*
- Drug susceptibility testing, of mycobacteria, 641-656, 685-686, 690
- BACTEC indirect qualitative test in, 645
- BACTEC indirect quantitative test in, 645-646
 in developing countries, 707
 luciferase indirect qualitative test in, 646-647
 methods for, 642-643
 principles of, 641-644
 proportion method in, 644-645
 quality control of, 662-663
 slide culture direct test in, 647-648
 of *Mycobacterium avium* complex, 648-652
 of *Mycobacterium fortuitum-chelonae*, 652-653

- of *Mycobacterium marinum*, 652-653
of *Mycobacterium tuberculosis*, 643-648
- Educational intervention, for test utilization control, 759-760
- ESP System, for mycobacterial culture, 562-563
- Ethambutol, pharmacokinetics of, 720-721
- Ethidium bromide, in polymerase chain reaction detection step, 625
- Ethionamide, pharmacokinetics of, 720-721
- Extraction, in polymerase chain reaction, 619-620
- Eye protection, for mycobacteriology, 540
- Fluorescent stains, for acid-fast bacteria, 554-555
- Gas-liquid chromatography, in mycobacterial identification, 605-606
- Gastric lavage, in specimen collection, for mycobacteriology, 552-553
- Gen-Probe MTD system, for polymerase chain reaction, in mycobacteriology, 632-634, 682-683
- Gloves, for mycobacteriology, 540-541
- Hawthorne effect, in performance, 758
- High-pressure liquid chromatography, in mycobacterial identification, 606-607
- HIV infection. See *Human immunodeficiency virus infection*.
- Horizontal laminar flow benches, in mycobacteriology, 535-536
- Human immunodeficiency virus infection, mycobacterial infections in, epidemiology of, 514-516
Mycobacterium avium complex infections in, drug susceptibility testing of, 648-650
tuberculosis in, in developing countries, 698-700
- Indirect tests, of drug susceptibility, of mycobacteria, 643-647
- Infectious substances, definition of, 543-544
- Infectious waste management, in mycobacteriology, 541-542
- Inoculation, in mycobacteriology, safety in, 530-531
- Iron uptake test, in mycobacterial identification, 583, 590-591
- Isoniazid, in mycobacterial infections, 641
pharmacokinetics of, 720-721
- Kanamycin, pharmacokinetics of, 720-721
- Kinyoun stain, for acid-fast bacteria, 554-555
- Labeling, of mycobacterial samples and cultures, 546-548
- Laboratory management, test utilization control in, 749-771
administrative interventions for, 765-768
approaches to, 749-750
caveats for, 751-752
clinical feedback in, 760-762
demand reduction in, 759-768
educational interventions for, 759-760
financial feedback in, 762-763
incentives for, 764-765
industry performance in, 752-754
organizational factors in, 755-756
physician profiling in, 763-764
published trials of, 758-759
quality of care and, 757-758
savings estimation in, 754-755
test ordering psychology in, 756-757
utilization measurement in, 750-751
- Lavage, in specimen collection, for mycobacteriology, 552-553
- Leprosy, epidemiology of, 513
- Lowenstein-Jensen culture media, for mycobacteria, 559-560
- Luciferase test, of drug susceptibility, of mycobacteria, 646-647
- MacConkey agar, in mycobacterial identification, 583, 591
- MB/BacT System, for mycobacterial culture, 562-563
- Microbial Identification System, in mycobacteriology, 605-606
- Microcolony method, for mycobacterial culture, 563-564, 604
- Microscopy, in mycobacteriology, 553-554
in developing countries, 706-707
- Middlebrook agar, for mycobacterial culture, 559-560
- Minimum inhibitory concentration, determination of, for mycobacteria, 642, 645-646
for *Mycobacterium avium* complex, 651-652

- Mycobacterial growth indicator tubes, 560-561
- Mycobacterial infections. See also *Tuberculosis*.
atypical. See also specific organism.
epidemiology of, 699
epidemiology of, 513-516
- Mycobacteriology, amplification techniques in, 617-639
- Association of State and Territorial Public Health Laboratory Directors recommendations on, 731-743
- automation in, culture equipment, 560, 562-563
- cultures in. See under *Cultures*.
- drug monitoring in, 717-729
- drug susceptibility testing in. See *Drug susceptibility testing, of mycobacteria*.
- epidemiology and, 513-516
- future developments in, 522-523
- identification techniques in, conventional, 569-601
approach to, 570
arylsulfatase method, 572, 578, 581, 583, 587
carbon usage measurement, 583, 587-588
catalase methods, 572, 578, 581, 583, 588-589
colonial morphology, 572, 578, 581, 583, 589-590
growth rate categorization, 570-571, 581
growth rate determination, 590
iron uptake measurement, 583, 590-591
- MacConkey agar growth rate, 583, 591
- NAP test, 591-592
- niacin production measurement, 572, 578, 581, 592
- nitrate reduction rate, 572, 578, 581, 583, 592-593
- nonphotochromogenicity in, 571-578
- photochromogenicity in, 570-571, 578-580
- pigment production, 572, 578, 581, 583, 593-594
- polymyxin B inhibition test, 583, 594
- pyrazinamide hydrolysis, 572, 578, 581, 594-595
- rapid growing capability, 582-586
role of, 569-570
- scotochromogenicity in, 580-582
- sodium chloride tolerance, 581, 583, 595
- species isolated in, 571
- TCH resistance, 573, 578, 581, 596-597
- tellurite reduction, 573, 595-596
- temperature studies, 572-573, 578, 581, 583, 596
- Tween 80 hydrolysis, 573, 578, 581, 597
- urease test, 573, 578, 581, 597-598
- in developing countries, 707-708, 711-712
- rapid, 603-615
- gas-liquid chromatography in, 605-606
- high-pressure liquid chromatography in, 606-607
- microcolony method in, 563-564, 604
- p-nitro- α -acetyl-amino- β -hydroxypropionophenone test in, 604-605
- nucleic acid probes in, 607-608
- nucleic acid sequencing in, 608-611
- quality control of, 662
- in developing countries, 520-522, 697-716
- disease control and, 700-701
- drug susceptibility testing, 707
- epidemiologic considerations in, 698-699
- identification testing, 707-708
- intermediate level laboratory in, 704
- laboratory networks in, 702-705
- new methods for, 710-712
- peripheral level laboratory in, 704
- protocols for, 712-713
- quality assurance in, 708-710
- reference laboratory in, 703-704
- services available for, 701-702
- specimen collection units in, 704-705
- technical standards and procedures for, 705-707
- laboratory for, 513-525
- polymerase chain reaction in, 617-639
- protocols for, in developing countries, 712-713
- in industrialized countries, 677-695
- algorithm for, 679-686
- clinical predictors vs. test pathways, 692-693
- cost-effective strategies, 686-689
- extent of service, 678-679
- future trends in, 689-690
- reference laboratory usage and, 686
- quality assurance in, 657-675
- safety in, 527-550
- services available for. See also *Mycobacteriology, in developing countries*.
in United States, 516-520
- specimen processing for, 551-567
- Mycobacterium abscessus*, identification of, 583
- Mycobacterium africanum*, identification of, 572-573

- Mycobacterium asiaticum*, identification of, 578-579
- Mycobacterium avium* complex, drug susceptibility testing of, 648-652
- epidemiology of, 515-516
- identification of, 572-574, 581
- Mycobacterium avium-intracellulare-scrofulaceum*, identification of, 580
- Mycobacterium bovis*, identification of, 572-573
- Mycobacterium branderi*, identification of, 572-575
- Mycobacterium celatum*, identification of, 572-573, 575
- Mycobacterium chelonae*, identification of, 583-585
- Mycobacterium conspicuum*, identification of, 572-573, 575
- Mycobacterium flavescens*, identification of, 580-581, 583
- Mycobacterium fortuitum* complex, identification of, 583-585
- Mycobacterium fortuitum-chelonae*, drug susceptibility testing of, 652-653
- Mycobacterium gastri*, identification of, 572-573, 575
- Mycobacterium genavense*, identification of, 572-573, 575
- Mycobacterium goodii*, identification of, 580-582
- isolation of, 559
- Mycobacterium haemophilum*, identification of, 572-573, 576
- Mycobacterium interjectum*, identification of, 581-582
- Mycobacterium intermedium*, identification of, 578-579
- Mycobacterium kansasii*, identification of, 578-579
- Mycobacterium lentiflavum*, identification of, 582
- Mycobacterium malmoense*, identification of, 572-573, 576
- Mycobacterium marinum*, drug susceptibility testing of, 652-653
- identification of, 578-579
- Mycobacterium mucogenicum*, identification of, 583
- Mycobacterium neoaurum*, identification of, 583, 585
- Mycobacterium paratuberculosis*, identification of, 576
- Mycobacterium phlei*, identification of, 585
- Mycobacterium scrofulaceum*, identification of, 581-582
- Mycobacterium shimoidei*, identification of, 572-573, 576-577
- Mycobacterium simiae*, identification of, 572-573, 578-580
- Mycobacterium smegmatis*, identification of, 583, 585
- Mycobacterium szulgai*, identification of, 578, 581-582
- Mycobacterium terrae* complex, identification of, 572-573, 577
- Mycobacterium thermoresistibile*, identification of, 583, 585
- Mycobacterium triviale*, identification of, 572-573, 577
- Mycobacterium tuberculosis* complex. See also *Tuberculosis*.
- bacteriology of. See *Mycobacteriology*.
- detection of, polymerase chain reaction in. See *Polymerase chain reaction*, in *mycobacteriology*.
- drug susceptibility testing of, 643-648
- identification of, 571-574
- infectious dose of, 529
- Mycobacterium ulcerans*, identification of, 572-573, 577
- Mycobacterium xenopi*, identification of, 572-573, 577-578, 581
- Mycolic acids, chromatography of, 607-608
- Niacin production test, in mycobacterial identification, 572, 578, 581, 592
- Nitrate reduction test, in mycobacterial identification, 572, 578, 581, 583, 592-593
- p-Nitro- α -acetylamino- β -hydroxypropiophenone test, in mycobacterial identification, 591-592, 604-605
- Nonphotochromogens, identification of, 571-578
- Nucleic acid probes, in mycobacterial identification, 607-608
- Nucleic acid sequencing, in mycobacterial identification, 608-611
- Packaging, of mycobacterial materials, 544-546
- PCR. See *Polymerase chain reaction*.
- Personal protective equipment, for mycobacteriology, 540-541
- Personnel, laboratory, in state laboratories, for mycobacteriology, 733-734
- tuberculin tests for, 542
- tuberculosis incidence in, 528
- Pharmacodynamics, of antimycobacterial drugs, 721
- Pharmacokinetics, of antimycobacterial drugs, 718-721
- Photochromogenicity, of mycobacteria, identification techniques based on, 570-571, 578-580
- Physicians, laboratory test use by, control of. See *Laboratory management, test utilization control in*.

- Pigment production, in mycobacterial identification, 572, 578, 581, 583, 593-594
- Polymerase chain reaction, in mycobacteriology, 617-639
 amplification approaches in, 621-623
 amplification targets in, 623-624
 cell lysis in, 619
 commercial systems for, 630-631
 definition of, 618-619
 detection schemes in, 625-626
 developmental challenges in, 629
 extraction methods in, 619-620
 implementation of, 634-637
 in developing countries, 711
 in-house vs. commercial, 631
 nested, 621-623
 principles of, 617-619
 purification methods in, 619-620
 sensitivity and specificity of, 626-629
 vs. Gen-Probe MTD system, 632-634
- Polymyxin B, in mycobacterial identification, 583, 594
- Probes, DNA, in mycobacteriology, quality control of, 661
 nucleic acid, in mycobacterial identification, 607-608
- Proficiency testing, in mycobacteriology, 669-672
- Proportion method, for drug susceptibility testing, of mycobacteria, 644-645
- Protocols, for mycobacteriology. See under *Mycobacteriology*.
- Purification, in polymerase chain reaction, 619-620
- Pyrazinamide, in mycobacterial identification, 572, 578, 581, 594-595
 in mycobacterial infections, 641-642
 in susceptibility testing, 646
 pharmacokinetics of, 720-721
- Quality assurance, in mycobacteriology, 657-675
 Association of State and Territorial Public Health Laboratory Directors recommendations on, 739-742
 definition of, 657
 in developing countries, 708-710
 in therapeutic drug monitoring, 725
 proficiency testing in, 669-672
 quality control in, 658-663
 quality improvement in, 664
 specimen-related issues in, 664-667
 test sensitivity and, 667-668
 test usage optimization in, 669
 test utilization reduction and, 757-758
 turnaround times and, 668-669
- Quality control, in mycobacteriology, 658-663
- Quality improvement, in mycobacteriology, 664
- Radiometric method, in drug susceptibility testing, in developing countries, 711-712
 of atypical mycobacteria, 653
 of *Mycobacterium avium* complex, 649-651
- Rapid techniques, in mycobacteria identification. See *Mycobacteriology, identification techniques in, rapid*.
- Rapidly growing mycobacteria, identification of, 582-586
- Reference laboratories, for mycobacteriology, 686
 in developing countries, 703-704
- Regulations, for mycobacterial sample handling, 544
- Respirators, for mycobacteriology, 541
- Rifabutin, pharmacokinetics of, 720-721
- Rifampin, pharmacokinetics of, 720-721
- RNA, amplification of, polymerase chain reaction in. See *Polymerase chain reaction*.
- Safety, in mycobacteriology, 527-550
 director role in, 542
 in level 2 laboratory, 538-539
 in level 3 laboratory, 539-540
 in routine procedures, 530-531
 in specimen transport, 543-548
 infectious waste management in, 541-542
 information sources for, 548
 medical surveillance in, 542-543
 personal protective equipment in, 540-541
 primary biocontainment in, 531-538
 relative risks vs. sample type, 528-530
 secondary biocontainment in, 538
 training for, 543
- Scotchromogens, identification of, 580-582
- Septi-Chek MB System, for mycobacterial culture, 564
- Slide culture test, of drug susceptibility, of mycobacteria, 647-648
- Smears, acid-fast. See *Acid-fast bacteria, smears of*.
- Sodium chloride tolerance test, in mycobacterial identification, 581, 583, 595
- Specimens, for mycobacteriology, 551-567

- collection of, 551-553
 in developing countries, 704-705
 cross-contamination of, 665-667
 decontamination of, 558-559, 660
 microscopic examination of, 553-554
 in developing countries, 706-707
 processing of, 557-559
 cost-effectiveness in, 687-688
 quality assurance in, 664-667
 safe handling of, 543-548
- Spill clean-up, in mycobacteriology, 541-542
- Sputum, mycobacterial studies of,
 collection of, 552
 sample handling in, 529
 for polymerase chain reaction,
 619-620
- Stains, for acid-fast bacteria, 554-555
- Stool specimens, for mycobacteriology, 553
- Streptomycin, pharmacokinetics of,
 720-721
- Susceptibility testing, of mycobacteria. See
*Drug susceptibility testing, of
 mycobacteria.*
- TCH test, in mycobacterial identification,
 573, 578, 581, 596-597
- Tellurite reduction, in mycobacterial
 identification, 573, 595-596
- Temperature studies, in mycobacterial
 identification, 572, 578, 581, 583, 596
- Tests, physician use of, control of. See
*Laboratory management, test utilization
 control in.*
- Thiacetazone, pharmacokinetics of,
 720-721
- Training, in mycobacteriology, Association
 of State and Territorial Public
 Health Laboratory Directors
 recommendations for, 739-741
 for safety, 543
- Transcription-mediated amplification, in
 mycobacteriology, 632-634
- Transport, of mycobacterial samples and
 cultures, 543-548
- Tuberculin tests, for laboratory personnel,
 542
- Tuberculosis, bacteriology of. See
Mycobacteriology.
 clinical features of, test pathways and,
 691
 control of, in developing countries, 700-
 701
 drug-resistant, 515
 in developing countries, 699-701
 epidemiology of, 513-516, 698-699
 in laboratory personnel, 528
 HIV infections with, 514-516
- Turbidimetric broth-dilution method, for
 drug susceptibility testing, of
Mycobacterium avium complex, 651-652
- Tween 80 hydrolysis test, in mycobacterial
 identification, 573, 578, 581, 597
- Urease test, in mycobacterial identification,
 573, 578, 581, 597-598
- Urine specimens, for mycobacteriology,
 553
 decontamination of, 559
- Waste, infectious, management of, in
 mycobacteriology, 541-542
- Zephiran, in mycobacterial specimen
 decontamination, 558
- Ziehl-Neelsen stain, for acid-fast bacteria,
 554-555